Key result
C-terminal Titin truncations caused severe myopathy whereas N-terminal mutations demonstrated mild phenotypes, explained by a conserved internal promoter that partially rescues N-terminal truncations.
Why the study?
Does the position of Titin truncation mutations (N- vs C-terminal) affect disease severity in a zebrafish model?
Does the position of Titin truncation mutations (N- vs C-terminal) affect disease severity in a zebrafish model?
The difference in disease severity between N- and C-terminal Titin truncation mutations is driven by a conserved internal promoter that partially rescues N-terminal truncations.
Titin truncation position may inform patient prognosis; leaves open human validation of promoter-based rescue.
Truncating mutations in the giant sarcomeric protein Titin result in dilated cardiomyopathy and skeletal myopathy. The most severely affected dilated cardiomyopathy patients harbor Titin truncations in the C-terminal two-thirds of the protein, suggesting that mutation position might influence disease mechanism. Using CRISPR/Cas9 technology, we generated six zebrafish lines with Titin truncations in the N-terminal and C-terminal regions. Although all exons were constitutive, C-terminal mutations caused severe myopathy whereas N-terminal mutations demonstrated mild phenotypes. Surprisingly, neither mutation type acted as a dominant negative. Instead, we found a conserved internal promoter at the precise position where divergence in disease severity occurs, with the resulting protein product partially rescuing N-terminal truncations. In addition to its clinical implications, our work may shed light on a long-standing mystery regarding the architecture of the sarcomere.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2015) studied Dilated cardiomyopathy and skeletal myopathy. Titin truncations in the N-terminal and C-terminal regions vs. N-terminal vs C-terminal mutations was evaluated on Disease severity and myopathy phenotype. C-terminal Titin truncations caused severe myopathy whereas N-terminal mutations demonstrated mild phenotypes, explained by a conserved internal promoter that partially rescues N-terminal truncations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: